# CanadaBuys #1000273405-1A

Health Canada in-vitro pharmacological testing of synthetic cannabinoids and stimulants

**Posted:** October 27, 2026
**Respond By:** November 09, 2026
**Identifier:** 1000273405-1A
**NAICS:** 541715, 541380

Health Canada is seeking laboratory partners to evaluate novel synthetic cannabinoids and stimulant compounds through two in-vitro testing streams.
- **Government buyer:** Government of Canada, Department of Health (Health Canada); the RFP identifies Shallee Doll and a Canadian Project Authority.
- **Requested services:** Stream 2 tests novel synthetic cannabinoids at human CB1 and CB2 receptors; Stream 3 tests stimulant compounds for dopamine uptake and release at DAT and VMAT2. Bidders may propose for either or both streams, and up to two contracts may be awarded.
- **Scope and quantities:** The solicitation summary describes 30 cannabinoids and 15 stimulants, plus two cannabinoid controls and three stimulant controls. The detailed cannabinoid attachment lists 29 test substances and two controls; the stimulant attachment lists 15 test substances and three controls.
- **Testing and deliverables:** Work includes sourcing substances and controls, obtaining necessary controlled-substance licences or authorizations and import permits, validating assays, experiments, statistical analysis, and draft and final reports. Cannabinoid assays measure binding affinity (Ki), maximum effect (Emax), potency (EC50), and signaling bias. Testing requires replicate experiments, qualified staff, suitable equipment, safety planning, and detailed data reporting. Additional stimulant uptake or efflux assays may be considered.
- **Named vendors and OEMs:** Cayman Chemical and Biosynth are mentioned as sourcing or pricing references, not required vendors. No OEM is specified.
- **Funding limits:** Maximum proposed prices are CAD 70,000 for Stream 2 and CAD 80,000 for Stream 3, before applicable taxes.
- **Performance period:** Approximately 16–18 months from award, with no option periods identified; the work is not described as an annual subscription.

### Description

Health Canada is seeking proposals for pharmacological testing in two separate streams: in vitro testing of novel synthetic cannabinoids and in vitro testing of stimulant compounds. The work includes obtaining reference standards and controls, securing required controlled-substance licenses, conducting experiments and statistical analyses, and preparing reports. Bidders may submit proposals for one or both streams, which will be evaluated separately; up to two contracts may be awarded. The stated contract term is estimated at 16 months, with work specified through March 31, 2028.

[View original listing](https://canadabuys.canada.ca/en/tender-opportunities/tender-notice/cb-912-87371785)